YI CHENG ZHI HUI LTD.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
AIxMed’s flagship solution, AIxURO™, is an AI-powered platform for urine cytology. It applies The Paris System for Reporting Urinary Cytology (TPS) to detect and classify atypical and suspicious cells, helping pathologists by offering quantitative risk an
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50894308
Status
Active
Number of Employees
0
Total capital
106,383,905 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AIxMed Inc., founded in 2018 and headquartered in Silicon Valley with a presence in Taiwan, is a health‑tech company that combines artificial intelligence with computational cytology. Their mission is to transform cancer diagnosis by applying machine learning and computer vision to cellular imaging, thereby improving diagnostic workflows and patient outcomes.
The content above was translated by Ai
